Truist lowered the firm’s price target on AMN Healthcare (AMN) to $47 from $50 and keeps a Buy rating on the shares. The company reported mixed Q3 results and issued downside Q4 guidance as EBITDA margins fell 500bps, the analyst tells investors in a research note. Truist adds however that demographic shifts, increasingly complex regulatory requirements, and AMN’s high quality interpreters should enable market share gain opportunities for the language services division.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
Questions or Comments about the article? Write to editor@tipranks.com